BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 22975846)

  • 1. Amphiphysin-1 protein level changes associated with tau-mediated neurodegeneration.
    De Jesús-Cortés HJ; Nogueras-Ortiz CJ; Gearing M; Arnold SE; Vega IE
    Neuroreport; 2012 Nov; 23(16):942-6. PubMed ID: 22975846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel calcium-binding protein is associated with tau proteins in tauopathy.
    Vega IE; Traverso EE; Ferrer-Acosta Y; Matos E; Colon M; Gonzalez J; Dickson D; Hutton M; Lewis J; Yen SH
    J Neurochem; 2008 Jul; 106(1):96-106. PubMed ID: 18346207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tauopathies and tau oligomers.
    Takashima A
    J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ezrin Expression is Increased During Disease Progression in a Tauopathy Mouse Model and Alzheimer's Disease.
    Vega IE; Umstead A; Wygant CM; Beck JS; Counts SE
    Curr Alzheimer Res; 2018; 15(12):1086-1095. PubMed ID: 30101710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy.
    Berger Z; Roder H; Hanna A; Carlson A; Rangachari V; Yue M; Wszolek Z; Ashe K; Knight J; Dickson D; Andorfer C; Rosenberry TL; Lewis J; Hutton M; Janus C
    J Neurosci; 2007 Apr; 27(14):3650-62. PubMed ID: 17409229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates.
    Vega IE; Cui L; Propst JA; Hutton ML; Lee G; Yen SH
    Brain Res Mol Brain Res; 2005 Aug; 138(2):135-44. PubMed ID: 15913839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration.
    Galán-Ganga M; Rodríguez-Cueto C; Merchán-Rubira J; Hernández F; Ávila J; Posada-Ayala M; Lanciego JL; Luengo E; Lopez MG; Rábano A; Fernández-Ruiz J; Lastres-Becker I
    Acta Neuropathol Commun; 2021 May; 9(1):90. PubMed ID: 34001284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deficiency of terminal complement pathway inhibitor promotes neuronal tau pathology and degeneration in mice.
    Britschgi M; Takeda-Uchimura Y; Rockenstein E; Johns H; Masliah E; Wyss-Coray T
    J Neuroinflammation; 2012 Sep; 9():220. PubMed ID: 22989354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer's disease and other tauopathies.
    Xia Y; Prokop S; Gorion KM; Kim JD; Sorrentino ZA; Bell BM; Manaois AN; Chakrabarty P; Davies P; Giasson BI
    Acta Neuropathol Commun; 2020 Jun; 8(1):88. PubMed ID: 32571418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
    Stancu IC; Ferraiolo M; Terwel D; Dewachter I
    Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies.
    Ferreira A; Bigio EH
    Mol Med; 2011; 17(7-8):676-85. PubMed ID: 21442128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylated p38MAPK specific antibodies cross-react with sarkosyl-insoluble hyperphosphorylated tau proteins.
    Sahara N; Vega IE; Ishizawa T; Lewis J; McGowan E; Hutton M; Dickson D; Yen SH
    J Neurochem; 2004 Aug; 90(4):829-38. PubMed ID: 15287888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brief update on different roles of tau in neurodegeneration.
    Ittner A; Ke YD; van Eersel J; Gladbach A; Götz J; Ittner LM
    IUBMB Life; 2011 Jul; 63(7):495-502. PubMed ID: 21698753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model.
    Helboe L; Egebjerg J; Barkholt P; Volbracht C
    Brain Res; 2017 Jun; 1665():22-35. PubMed ID: 28411086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel autoimmune response in a tauopathy mouse model.
    Nogueras-Ortiz CJ; De Jesús-Cortes HJ; Vaquer-Alicea J; Vega IE
    Front Neurosci; 2014 Jan; 7():277. PubMed ID: 24454278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GSPE interferes with tau aggregation in vivo: implication for treating tauopathy.
    Santa-Maria I; Diaz-Ruiz C; Ksiezak-Reding H; Chen A; Ho L; Wang J; Pasinetti GM
    Neurobiol Aging; 2012 Sep; 33(9):2072-81. PubMed ID: 22054871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated neurodegeneration and neuroinflammation in transgenic mice expressing P301L tau mutant and tau-tubulin kinase 1.
    Asai H; Ikezu S; Woodbury ME; Yonemoto GM; Cui L; Ikezu T
    Am J Pathol; 2014 Mar; 184(3):808-18. PubMed ID: 24418258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered Proteostasis in Neurodegenerative Tauopathies.
    Papanikolopoulou K; Skoulakis EMC
    Adv Exp Med Biol; 2020; 1233():177-194. PubMed ID: 32274757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Picalm reduction exacerbates tau pathology in a murine tauopathy model.
    Ando K; De Decker R; Vergara C; Yilmaz Z; Mansour S; Suain V; Sleegers K; de Fisenne MA; Houben S; Potier MC; Duyckaerts C; Watanabe T; Buée L; Leroy K; Brion JP
    Acta Neuropathol; 2020 Apr; 139(4):773-789. PubMed ID: 31925534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of tauopathies with transgenic mice.
    Hutton M; Lewis J; Dickson D; Yen SH; McGowan E
    Trends Mol Med; 2001 Oct; 7(10):467-70. PubMed ID: 11597522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.